The expanded Catalyst for
a Cure research consortium includes David Calkins, PhD, Vanderbilt University; Alfredo Dubra, PhD, Medical College of Wisconsin; Jeffrey Goldberg, MD, PhD, Shiley Eye Center, University of California San Diego; Philip Horner, PhD, University of Washington; Andrew Huberman, PhD, University of California San Diego; Nicholas Marsh - Armstrong, PhD, Johns Hopkins University; Vivek Srinivasan, PhD, University of California Davis; and Monica Vetter, PhD, University of Utah.
The expanded Catalyst for
a Cure research consortium includes David Calkins, PhD, Vanderbilt University; Alfredo Dubra, PhD, Medical College of Wisconsin; Jeffrey Goldberg, MD, PhD, Bascom Palmer Eye Institute; Philip Horner, PhD, University of Washington; Andrew Huberman, PhD, University of California, San Diego; Nicholas Marsh - Armstrong, PhD, Johns Hopkins University; Vivek Srinivasan, PhD, Massachusetts General Hospital; and Monica Vetter, PhD, University of Utah.
March 14, 2012, San Francisco — Glaucoma Research Foundation (GRF) announced today that it will double its Catalyst for
a Cure research consortium to eight research scientists from prestigious universities across the United States.
Not exact matches
For example, a
consortium of
research groups called the London Project to
Cure Blindness aims to test RPE transplants from embryonic stem cells in patients with macular degeneration this year.
In addition to funding innovative
research like the Catalyst for a Cure consortium and Shaffer Grants, Glaucoma Research Foundation provides free educational material including the definitive reference for newly diagnosed patients, «Understanding and Living with Glaucoma,» brochures serving those at highest risk including African Americans and Latinos, and a comprehensive website www.glaucoma.org that answers patients» questions about g
research like the Catalyst for a
Cure consortium and Shaffer Grants, Glaucoma
Research Foundation provides free educational material including the definitive reference for newly diagnosed patients, «Understanding and Living with Glaucoma,» brochures serving those at highest risk including African Americans and Latinos, and a comprehensive website www.glaucoma.org that answers patients» questions about g
Research Foundation provides free educational material including the definitive reference for newly diagnosed patients, «Understanding and Living with Glaucoma,» brochures serving those at highest risk including African Americans and Latinos, and a comprehensive website www.glaucoma.org that answers patients» questions about glaucoma.
Our Catalyst For a
Cure (CFC) collaborative
research consortium has brought important new ideas to the glaucoma field and has expanded knowledge of the mechanisms by which retinal ganglion cells are damaged and die in glaucoma.
Our Catalyst For a
Cure (CFC) collaborative
research consortium has brought important new ideas to the glaucoma field.
As director of the pediatric motor disorders
research program at the University of Utah School of Medicine in Salt Lake City, she led the Project
Cure SMA Investigators Network, a trial
consortium that recently published the results of two placebo - controlled trials of the HDAC - blocking agent valproic acid, neither of which demonstrated much clinical advantage from the drug1, 2.
The Delaney Collaboratory to
Cure HIV - 1 Infection by Combination Immunotherapy (BEAT - HIV Collaboratory) is a
consortium of more than 30 top HIV researchers from leading academic
research institutions working with government, nonprofit organizations, and industry partners to test combinations of several novel immunotherapies under new preclinical
research and clinical trials.